GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Infusions Ltd (DHA:ORIONINFU) » Definitions » EV-to-Revenue

Orion Infusions (DHA:ORIONINFU) EV-to-Revenue : 9.79 (As of Jun. 25, 2025)


View and export this data going back to . Start your Free Trial

What is Orion Infusions EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Orion Infusions's enterprise value is BDT6,609.1 Mil. Orion Infusions's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was BDT675.1 Mil. Therefore, Orion Infusions's EV-to-Revenue for today is 9.79.

The historical rank and industry rank for Orion Infusions's EV-to-Revenue or its related term are showing as below:

DHA:ORIONINFU' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.57   Med: 2.43   Max: 24.71
Current: 9.79

During the past 13 years, the highest EV-to-Revenue of Orion Infusions was 24.71. The lowest was 1.57. And the median was 2.43.

DHA:ORIONINFU's EV-to-Revenue is ranked worse than
86.73% of 972 companies
in the Drug Manufacturers industry
Industry Median: 2.39 vs DHA:ORIONINFU: 9.79

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-25), Orion Infusions's stock price is BDT310.20. Orion Infusions's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was BDT33.22. Therefore, Orion Infusions's PS Ratio for today is 9.34.


Orion Infusions EV-to-Revenue Historical Data

The historical data trend for Orion Infusions's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orion Infusions EV-to-Revenue Chart

Orion Infusions Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.42 2.31 2.50 8.86 12.18

Orion Infusions Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.67 12.18 9.51 11.50 12.25

Competitive Comparison of Orion Infusions's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Infusions's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Orion Infusions's EV-to-Revenue falls into.


;
;

Orion Infusions EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Orion Infusions's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=6609.119/675.084
=9.79

Orion Infusions's current Enterprise Value is BDT6,609.1 Mil.
Orion Infusions's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT675.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orion Infusions  (DHA:ORIONINFU) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Orion Infusions's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=310.20/33.219
=9.34

Orion Infusions's share price for today is BDT310.20.
Orion Infusions's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT33.22.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orion Infusions EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Orion Infusions's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Orion Infusions Business Description

Traded in Other Exchanges
N/A
Address
153-154 Tejgaon I/A, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company. It produces various types of intravenous fluids, rehydration solutions, electrolyte solutions, antimicrobial products, and other pharmaceutical products in Bangladesh. The products of the company include Dextrolac, Dextropac, Dextrosal, Dianak, Electro dex, fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the company is also involved in activities related to cosmetics and toiletries, infrastructure development, real estate and construction, power, agro products, hospitality, textiles and garments, and aviation management sectors. Geographically, it operates in Bangladesh.

Orion Infusions Headlines

No Headlines